www.feizichem.com   Shijiazhuang FeiZi Chemical Technology Co., Ltd.

Recently, the National Development and Reform Commission and the State Administration for Market Regulation jointly issued the “Notice on Matters Related to Cost Accounting for Low-Price, Disordered Competition in Key Industrial Products” (NDRC Price [2026] No. 1303). In response to the issue of low-price, disorderly competition in certain key industrial sectors, the notice further standardizes cost accounting and guides the industry back onto a path of reasonable pricing. In light of this policy direction, Shijiazhuang Feizi Chemical Technology Co., Ltd., a fine chemical enterprise based in Shijiazhuang, stated that it has long adhered to the business principle of “determining costs through quality and setting prices based on costs,” refraining from engaging in cutthroat price competition and instead focusing its R&D and quality-control capabilities on high-value-added key intermediate products.

An “invisible” active pharmaceutical ingredient: DBTO underpins the reputation of high-end intermediates

Within Feizhi Chemical’s product portfolio,  10,11-Dihydro-11-oxodibenzo[b,f][1,4]thiazepine ( DBTO; CAS No. 3159077) is one of its key premium offerings. This compound is a heterocyclic pharmaceutical intermediate that, owing to its seven-membered sulfur–nitrogen ring core, primarily supports the synthesis of downstream active pharmaceutical ingredients, particularly psychotropic drugs. It demands exceptionally high purity, stringent control of individual impurities, and consistent batch-to-batch stability, making it a category characterized by high technical barriers and an inability to compete solely on price. According to reports, Feizi Chemical has established end-to-end quality control—covering everything from synthesis processes to purification, drying, and packaging—for DBTO (CAS 3159-07-7). The product is now available on the company’s official website and has been simultaneously launched on multiple mainstream chemical platforms, creating a relatively comprehensive online inquiry and delivery network.

Policy Implementation: Only by accurately calculating the “costs” can we safeguard the “quality”.

At the heart of Document No. 1303 is the requirement that key industrial producers and operators accurately calculate their costs and refrain from disrupting the market by selling below cost. According to a responsible official at Feizi Chemical, this policy is “positive” for companies that genuinely invest in R&D and quality—historically, the market for similar intermediates has been plagued by substandard products being passed off as highquality and by aggressive pricedriven orderwinning, ultimately harming downstream pharmaceutical firms and endusers. With standardized cost accounting, products like DBTO (CAS 3159077), which rely on stable process expertise, will see their true value more widely recognized by customers.

“In the fine chemicals industry, it’s never about the lowest price—it’s about delivering the same quality batch after batch, time and again,” said the company official. The company will continue to allocate resources to product categories with strong technological barriers, such as heterocyclic intermediates, dye intermediates, and pharmaceutical intermediates. It will also strengthen supply-chain traceability and cost transparency around flagship products like DBTO (CAS 3159-07-7), proactively align with regulatory requirements, and operate under the dual oversight of customers and regulators.

The company will take the issuance of this policy as an opportunity to further refine the cost and quality benchmarks of its more than one hundred instock products, while continuing to deepen its presence in Shijiazhuang in the fields of custom synthesis and intermediate supply for the fine chemicals sector, thereby helping the industry transition from “lowprice, cutthroat competition” to “valuebased competition.”